Skip to content
OpenCapital
Get started

Anika Therapeutics ANIK Enterprise value

Enterprise value at other companies

Stryker logo
StrykerSYK
$137.35B-12.4%
Vericel logo
VericelVCEL
$1.62B-28.0%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$24.74B-12.7%
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$1.18B-3.4%
Bioventus logo
BioventusBVS
$867.64M-8.5%
Xtant Medical Holdings logo
Xtant Medical HoldingsXTNT
$80.98M-2.4%

Other financials

Income statement

See full
Revenue$29.6M+13.2%
Net income-$5.1M-3.8%

Balance sheet

See full
Cash & equivalents$41.0M-23.1%
Total debt$25.7M+1.2%
Total equity$133.9M-9.8%
Total assets$179.4M-5.9%

Cash flow

See full
Operating cash flow-$4.8M-3,628%
CapEx$1.4M-49.3%
Free cash flow-$6.3M-112%

Valuation

See full
Market cap$204.37M+31.6%
P/S1.8×+0.1×

Profitability

See full
Net margin-9.8%-4.4pp
FCF margin0.9%—

Returns & leverage

See full
Return on equity-8%-3.4pp
Debt / equity0.2×0.0×
Current ratio4.5×-1.3×

Where this comes from

Calculated from Anika Therapeutics’s reported figures.

$194.3Mmarket cap+$25.7Mtotal debt−$41.0Mcash and equivalents=$179.03M

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Anika Therapeutics's enterprise value?
Anika Therapeutics (ANIK) reported enterprise value of $179.03M in Q1 2026.
How has Anika Therapeutics's enterprise value changed year-over-year?
Anika Therapeutics's enterprise value decreased by 3.3% year-over-year, from $185.13M to $179.03M.
What is the long-term trend for Anika Therapeutics's enterprise value?
Over 5 years (2020 to 2025), Anika Therapeutics's enterprise value has grown at a -28.6% compound annual growth rate (CAGR), from $579.97M to $107.35M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.